Company intelligence / Profile preview

Shenzhen Hornetcorn Biotechnology Co., Ltd.

_not_specified_, _not_specified_, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 1

Overview

The company is developing cellular therapies for cancer and autoimmune diseases. Its lead programs use human umbilical cord-derived mesenchymal stem cells for rheumatoid arthritis, DC-CIK therapies for colorectal cancer and esophageal carcinoma, and DC–CTLs for non-small cell lung cancer. Clinical trials are ongoing or pending; no late-stage results reported as of now.[1][3]

Therapeutic areas: OncologyImmunology
Modalities: Mesenchymal stem cells (MSC)Dendritic cell–activated cytokine-induced killer cells (DC-CIK)Dendritic cell–activated cytotoxic T lymphocytes (CTLs)[1][3]
Industry: Biotech

Drug pipeline

7 assets

Ag-D-CIK

6 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Shenzhen Hornetcorn Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Hornetcorn Biotechnology Co., Ltd..

Explore the full profile